US Stock Insider Trading | Lyell Immunopharma disclosed four insider transactions on February 11

K-LinePoet · 2026-02-25T05:54:18+00:00

On February 11, 2026, Lyell Immunopharma disclosed insider trading activities involving several executives and directors, including Seely Lynn and Bulis Veronica Sanchez, who sold shares on February 10 at a trading price of $23.12. The company is a clinical-stage cell therapy company dedicated to developing CAR T-cell therapies for cancer treatment.

K-LinePoet

2026-02-25 05:54:18

Abstract generation in progress

On February 11, 2026, Lyell Immunopharma (LYEL) disclosed four insider trades. Director Seely Lynn sold 438 shares on February 10, 2026.

[Recent Insider Trades]

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 11, 2026	Executive	Lee Gary K.	February 10, 2026	Sell	147	23.12	3,398.64
February 11, 2026	Director	Seely Lynn	February 10, 2026	Sell	438	23.12	10,100.00
February 11, 2026	Executive	Bulis Veronica Sanchez	February 10, 2026	Sell	254	23.12	5,872.48
February 11, 2026	Executive	Hill Stephen J.	February 10, 2026	Sell	109	23.12	2,520.08
January 6, 2026	Executive	Bulis Veronica Sanchez	December 30, 2025	Sell	936	32.32	32,000.00
January 6, 2026	Executive	Bulis Veronica Sanchez	December 24, 2025	Sell	1,136	38.67	43,900.00
November 12, 2025	Executive	Bulis Veronica Sanchez	November 10, 2025	Sell	239	16.10	3,847.90
November 12, 2025	Executive	Lee Gary K.	November 10, 2025	Sell	138	16.16	2,230.08
November 12, 2025	Executive	Hill Stephen J.	November 10, 2025	Sell	95	16.12	1,531.40
August 22, 2025	Executive	Lee Gary K.	August 21, 2025	Sell	1,453	10.54	15,300.00

[Company Profile]

Lyell Immunopharma, Inc. was incorporated in Delaware in June 2018. The company is a clinical-stage cell therapy firm expected to enter pivotal trials in 2025, advancing proprietary next-generation autologous CAR T-cell candidate pipelines for hematologic malignancies and solid tumors. The company is pioneering new approaches aimed at generating T cells that drive durable clinical responses. The patient’s live cells are the starting point for the company’s research-based CAR T-cell therapies, enhanced through innovative CAR structures, technologies, and manufacturing protocols.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.